MULTIPLE SCLEROSIS, RELAPSING-REMITTING

This study tested clemastine fumarate, an old allergy medicine, to see if it could repair damaged nerves in people with relapsing-remitting multiple sclerosis (MS). Fifty adults with MS took either the drug or a placebo for up to 3 months while continuing their usual MS treatment…

This early-phase study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis (MS). ECP involves filtering a person's blood, treating it with light, and returning it to the body. The goal was to see if it is safe and might help improve w…

This study looked at 94 adults with relapsing-remitting multiple sclerosis to better understand why some people have more trouble walking than others. Researchers used advanced MRI scans to measure damage in brain and spinal cord pathways that control movement and sensation. The …

This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their current medication to ozanimod. Researchers wanted to understand the reasons for the switch—such as lack of effectiveness, side effects, or patient preference—and how the switch …

This study looked at how well thinking skills (like memory and attention) are captured by a virtual reality test compared to standard paper tests in people with relapsing-remitting multiple sclerosis (RRMS) taking the medication Aubagio. Researchers followed 75 patients and healt…

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) who were already prescribed ozanimod (Zeposia). Researchers collected real-world data over 3 years to see how long patients stayed on the drug, how it affected their quality of life, and what side e…